Directed Therapies in Lung Cancer: New Hope?

被引：3

作者：

Parente Lamelas, Isaura ^{[1
]}

Abal Arca, Jose ^{[1
]}

Firvida Perez, Jose Luis ^{[2
]}

机构：

[1] Complexo Hosp Univ Ourense, Serv Neumol, Orense, Spain

[2] Complexo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain

来源：

ARCHIVOS DE BRONCONEUMOLOGIA | 2012年 / 48卷 / 10期

关键词：

Lung cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Anaplastic lymphoma kinase; Erlotinib; Gefitinib; Bevacizumab; Crizotinib; GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PHASE-III; OPEN-LABEL; 1ST-LINE THERAPY; GEFITINIB; MUTATIONS; SURVIVAL; ERLOTINIB; CHEMOTHERAPY;

D O I：

10.1016/j.arbres.2012.03.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK). (c) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.

引用

页码：367 / 371

页数：5

共 50 条

[1] Responses to targeted therapies: lung cancer
Brambilla, Elisabeth
ANNALES DE PATHOLOGIE, 2009, 29 : S77 - S80
[2] Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists
Costantini, Adrien
Katsikas, Theodoros
Bostantzoglou, Clementine
CURRENT RESPIRATORY MEDICINE REVIEWS, 2020, 16 (01) : 5 - 10
[3] Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians
Rolfo, Christian
Passiglia, Francesco
Ostrowski, Marcin
Farracho, Lucia
Ondoichova, Tereza
Dolcan, Ana
Castiglia, Marta
Remmen, Roy
Papadimitriou, Konstantinos
Pauwels, Patrick
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2015, 28 (01) : 124 - 133
[4] Metastatic lung cancer in the age of targeted therapy: improving long-term survival
Del Rivero, Jaydira
Enewold, Lindsey
Thomas, Anish
TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (06) : 727 - 730
[5] Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care
Quinn, Zachary L.
Barta, Julie A.
Johnson, Jennifer M.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2022, 364 (04) : 371 - 378
[6] Target Therapies in Lung Cancer
Bearz, A.
Berretta, M.
Lleshi, A.
Tirelli, U.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
[7] Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of "Master Protocols" in Lung Cancer
Malik, Shakun M.
Pazdur, Richard
Abrams, Jeffrey S.
Socinski, Mark A.
Sause, William T.
Harpole, David H., Jr.
Welch, John J.
Korn, Edward L.
Ullmann, Claudio Dansky
Hirsch, Fred R.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1443 - 1448
[8] New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer
Provencio, Mariano
Sanchez, Antonio
Garrido, Pilar
Valcarcel, Francisco
CLINICAL LUNG CANCER, 2010, 11 (02) : 91 - 97
[9] Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database
Kobayashi, Keigo
Soejima, Kenzo
Fukunaga, Koichi
Shintani, Yasushi
Sekine, Ikuo
Shukuya, Takehito
Takayama, Koichi
Inoue, Akira
Okamoto, Isamu
Kiura, Katsuyuki
Takahashi, Kazuhisa
Yamamoto, Nobuyuki
Takiguchi, Yuichi
Miyaoka, Etsuo
Okumura, Meinoshin
Yoshino, Ichiro
LUNG CANCER, 2020, 146 : 236 - 243
[10] Targeted Therapy for Non-Small Cell Lung Cancer
Jett, James R.
Carr, Laurie L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (08) : 907 - 912

← 1 2 3 4 5 →